Aardvark Therapeutics Inc (NASDAQ: AARD)’s stock price has gone rise by 10.39 in comparison to its previous close of 7.51, however, the company has experienced a -8.80% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-03-31 that SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the full year ended December 31, 2024, and provided business highlights.
Is It Worth Investing in Aardvark Therapeutics Inc (NASDAQ: AARD) Right Now?
There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AARD is 12.21M, and at present, short sellers hold a 2.72% of that float. The average trading volume of AARD on April 02, 2025 was 192.04K shares.
AARD’s Market Performance
The volatility ratio for the week is 18.98%, and the volatility levels for the last 30 days are 14.40% for Aardvark Therapeutics Inc (AARD). The simple moving average for the past 20 days is -12.69% for AARD’s stock, with a -25.58% simple moving average for the past 200 days.
Analysts’ Opinion of AARD
Many brokerage firms have already submitted their reports for AARD stocks, with RBC Capital Mkts repeating the rating for AARD by listing it as a “Outperform.” The predicted price for AARD in the upcoming period, according to RBC Capital Mkts is $21 based on the research report published on March 10, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see AARD reach a price target of $29. The rating they have provided for AARD stocks is “Overweight” according to the report published on March 10th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to AARD, setting the target price at $50 in the report published on March 10th of the current year.
AARD Trading at -25.58% from the 50-Day Moving Average
After a stumble in the market that brought AARD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.66% of loss for the given period.
Volatility was left at 14.40%, however, over the last 30 days, the volatility rate increased by 18.98%, as shares sank -30.92% for the moving average over the last 20 days.
During the last 5 trading sessions, AARD fell by -8.80%, in comparison to the 20-day moving average, which settled at $9.49. In addition, Aardvark Therapeutics Inc saw -42.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AARD starting from Decheng Capital Global Life Sc, who purchase 1,250,000 shares at the price of $16.00 back on Feb 14 ’25. After this action, Decheng Capital Global Life Sc now owns 2,958,887 shares of Aardvark Therapeutics Inc, valued at $20,000,000 using the latest closing price.
Lee Tien-Li, the Chief Executive Officer of Aardvark Therapeutics Inc, purchase 16,542 shares at $16.00 during a trade that took place back on Feb 14 ’25, which means that Lee Tien-Li is holding 1,496,175 shares at $264,672 based on the most recent closing price.
Stock Fundamentals for AARD
The liquidity ratio also appears to be rather interesting for investors as it stands at 31.65.
Conclusion
In summary, Aardvark Therapeutics Inc (AARD) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
